SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-094347
Filing Date
2024-08-09
Accepted
2024-08-09 07:30:28
Documents
68
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q akro-20240630.htm   iXBRL 10-Q 2713333
2 EX-10.1 akro-ex10_1.htm EX-10.1 16061
3 EX-31.1 akro-ex31_1.htm EX-31.1 16190
4 EX-31.2 akro-ex31_2.htm EX-31.2 15932
5 EX-32.1 akro-ex32_1.htm EX-32.1 13374
  Complete submission text file 0000950170-24-094347.txt   10482995

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT akro-20240630.xsd EX-101.SCH 1309583
70 EXTRACTED XBRL INSTANCE DOCUMENT akro-20240630_htm.xml XML 2001232
Mailing Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 650-487-6488
Akero Therapeutics, Inc. (Filer) CIK: 0001744659 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38944 | Film No.: 241190405
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)